- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Novel Formulations of a Liver Protection Drug Glycyrrhizin
-
- KOGA Kenjiro
- Faculty of Pharmaceutical Sciences, Hokuriku University
-
- KAWASHIMA Susumu
- Faculty of Pharmaceutical Sciences, Hokuriku University
-
- SHIBATA Nobuhito
- Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts
-
- TAKADA Kanji
- Kyoto Pharmaceutical University
Bibliographic Information
- Other Title
-
- 肝庇護治療薬グリチルリチンの新しい製剤化の試み
- カン ヒゴ チリョウヤク グリチルリチン ノ アタラシイ セイザイカ ノ ココロミ
Search this article
Description
In Japan, glycyrrhizin injections have been used as a therapeutic drug for allergy inflammation since 1948 and for chronic hepatitis since 1979. A 20 ml injection of glycyrrhizin contains 53 mg of monoammonium glycyrrhizinate (40 mg as glycyrrhizin acid), 400 mg of glycine, and 20 mg of L-cysteine. Patients receiving glycyrrhizin injections two or three times per week are forced to accept a decline in quality of life. Because administering glycyrrhizin by injection has some disadvantages, many researchers have systematically searched for novel glycyrrhizin formulations that can be administered through oral, rectal, intranasal, and subcutaneous routes. There are two problems, however, in developing new formulations: (1) glycyrrhizin has low membrane permeability and is thus poorly absorbed, and (2) highly concentrated glycyrrhizin readily forms gels in aqueous solutions. Here, we describe the utility of glycyrrhizin formulations prepared in safe solubility agents and absorption-enhancing agents, as assessed in animal experiments. We also discuss pharmaceutical issues in developing various glycyrrhizin formulations. In the near future, convenient pharmaceutical preparations of glycyrrhizin will be developed for chronic hepatitis patients who require glycyrrhizin therapy.<br>
Journal
-
- YAKUGAKU ZASSHI
-
YAKUGAKU ZASSHI 127 (7), 1103-1114, 2007-07-01
The Pharmaceutical Society of Japan
- Tweet
Details 詳細情報について
-
- CRID
- 1390001206128021248
-
- NII Article ID
- 110006318159
-
- NII Book ID
- AN00284903
-
- COI
- 1:STN:280:DC%2BD2szos1eqsA%3D%3D
-
- ISSN
- 13475231
- 00316903
-
- NDL BIB ID
- 8881973
-
- PubMed
- 17603270
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed